Skip to main content

Invasive Pneumococcal Bacteremia in a 9-Year-Old Boy Caused by Serotype 1: Course, Treatment and Costs

  • Conference paper
  • First Online:
Respiratory Regulation - Clinical Advances

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 755))

  • 2970 Accesses

Abstract

Streptococcus pneumoniae is a leading cause of bacteremia, sepsis, meningitis, pneumonia, sinusitis, and acute otitis media in young children. Some serotypes are associated with particular disease syndromes, such as complicated pneumonias in children, or with higher rates of hospitalization in children and are consistently responsible for outbreaks in certain populations. In this report we describe a case of a nine-year-old boy who developed an abscess of pleura and invasive pneumococcal bacteremia. The boy was admitted to the hospital with abdominal pain and vomiting, accompanied by mild cough and fever. Chest X-ray revealed lower left lobe consolidation with pleural inflammation and chest CT showed extensive interstitial-alveolar changes in the left lung with atelectasis and pleural effusion causing a reduction in lung volume up to the fourth rib. From the 6th day of hospitalization on, suction drainage and intrapleural administration of alteplase were continued for 5 days. Intravenous antibiotics were administered for subsequent 32 days. The course of disease was complicated with labial herpes and acute adenoviral gastroenteritis. The costs of diagnosis (11.7%), pharmacotherapy (55.2%), hospitalization (30.7%) and additional procedures (2.4%) were about €4,444, while the cost of treatment from the perspective of the National Health Fund was only €1,508. The costs of treating the boy with sepsis caused by S. pneumoniae serotype 1 were thus about three times higher than those from the perspective of providers of the National Health Fund. Administration of a new pneumococcal conjugated vaccine containing serotype 1 (PHiD-CV10 or PCV13) could have prevented invasive pneumococcal disease in the described patient.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Advisory Committee on Immunisation Practices. (2000). Preventing pneumococcal disease among infants and young children: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports, 45((RR-9)), 1–35.

    Google Scholar 

  • American Academy of Pediatrics. (2000). Policy statement: Recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis. Pediatrics, 106, 362–366.

    Article  Google Scholar 

  • Bergman, A., Hjelmgren, J., Ortqvist, A., Wisløff, T., Kristiansen, I. S., Högberg, L. D., Persson, K. M., & Persson, U. (2008). Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden. Scandinavian Journal of Infectious Diseases, 40(9), 721–729.

    Article  PubMed  Google Scholar 

  • Beutels, P., Van Damme, P., & Osterhuis-Kafeja, F. (2006). Effects and costs of pneumococcal conjugate vaccination of Belgian children. KCE reports, 33C. Belgian Health Care Knowledge Centre. Retrieved on July 2, 2011, from http://www.kce.fgov.be/index_en.aspx?SGREF=5220

  • CDC. (2008). Updated Recommendation from the Advisory Committee on Immunisation Practices (ACIP) for use of 7-valent pneumococcal conjugate vaccine (pcv7) in children aged 24-59 months who are not completely vaccinated. MMWR Weekly, 57(13), 343–344.

    Google Scholar 

  • Centers for Disease Control and Prevention. (2000). Preventing pneumococcal disease among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recommendations and Reports, 49(RR-9), 1–38.

    Google Scholar 

  • Claes, C., Reinert, R. R., & der Schulenburg, J. M. (2009). Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects. The European Journal of Health Economics, 10(1), 25–38.

    Article  PubMed  Google Scholar 

  • Ess, S. M., Schaad, U. B., Gervaix, A., Pinosch, S., & Szucs, T. D. (2003). Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland. Vaccine, 21(23), 3273–3281.

    Article  PubMed  Google Scholar 

  • European Central Bank. (2011). Eurosystem. Euro exchange rates. Retrieved on July 2, 2011, from http://www.ecb.int/stats/exchange/eurofxref/html/eurofxref-graph-gbp.en.html

  • Grzesiowski, P., Skoczynska, A., Albrecht, P., Konior, R., Patrzałek, M., Sadowska, M., Staroszczyk, J., Szenborn, L., Wysocki, J., Hryniewicz, W., & Polish Pediatric IPD Group. (2008). Invasive pneumococcal disease in children up to 5 years of age in Poland. European Journal of Clinical Microbiology & Infectious Diseases, 27(9), 883–885.

    Article  CAS  Google Scholar 

  • Hamblin, S. E., & Furmanek, D. L. (2010). Intrapleural tissue plasminogen activator for the treatment of parapneumonic effusion. Pharmacotherapy, 30(8), 855–862.

    Article  PubMed  CAS  Google Scholar 

  • Hausdorff, W. P. (2007). The roles of pneumococcal serotypes 1 and 5 in pediatric invasive disease. Vaccine, 25, 2406–2412.

    Article  PubMed  Google Scholar 

  • Hausdorff, W. P., Bryant, J., Paradiso, P. R., & Siber, G. R. (2000). Which pneumococcal serogroups cause the most invasive disease: Implications for conjugate vaccine formulation and use, Part I. Clinical Infectious Diseases, 30, 100–121.

    Article  PubMed  CAS  Google Scholar 

  • Hawkins, J. A., Scaife, E. S., Hillman, N. D., & Feola, G. P. (2004). Current treatment of pediatric empyema. Seminars in Thoracic and Cardiovascular Surgery, 16(3), 196–200.

    Article  PubMed  Google Scholar 

  • Jackowska, T., & Kłyszewska, M. (2010). Implementation of the recommended vaccinations for children and assessment of awareness of their parents. Pediatria Polska, 85(3), 201–206 (Article in Polish).

    Article  Google Scholar 

  • Koegelenberg, C. F. N., Diacon, A. H., & Bolliger, C. T. (2008). Parapneumonic pleural effusion and empyema. Respiration, 75, 241–250.

    Article  PubMed  Google Scholar 

  • Marchetti, M., & Colombo, G. L. (2005). Cost-effectiveness of universal pneumococcal vaccination for infants in Italy. Vaccine, 23(37), 4565–4576.

    Article  PubMed  CAS  Google Scholar 

  • McIntosh, E. D., Conway, P., Willingham, J., & Lloyd, A. (2003). The cost-burden of paediatric pneumococcal disease in the UK and the potential cost-effectiveness of prevention using 7-valent pneumococcal conjugate vaccine. Vaccine, 21(19–20), 2564–2572.

    Article  PubMed  Google Scholar 

  • National Health Fund. (2011). Catalogue of diagnosed related group (JGP). Poland: National Health Fund (NFZ). Retrieved on July 2, 2011, from http://www.nfz.gov.pl

  • OECD. (2011). StatExtracts. Consumer price index. Retrieved on July 2, 2011, from http://stats.oecd.org/Index.aspx?DataSetCode=MEI_PRICES

  • OECD. (2011). StatExtracts. Purchasing power parities. Retrieved on July 2, 2011, from http://stats.oecd.org/Index.aspx?DataSetCode=MEI_PRICES

  • Rozenbaum, M. H., Sanders, E. A., van Hoek, A. J., Jansen, A. G., van der Ende, A., van den Dobbelsteen, G., Rodenburg, G. D., Hak, E., & Postma, M. J. (2010). Cost effectiveness of pneumococcal vaccination among Dutch infants: economic analysis of the 7-valent pneumococcal conjugated vaccine and forecast for the 10 valent and 13 valent vaccines. British Medical Journal, 340, c2509.

    Article  PubMed  Google Scholar 

  • Ruckinger, S., von Kries, R., Siedler, A., & van der Linden, M. (2009). Association of serotype of Streptococcus pneumoniae with risk of severe and fatal outcome. Pediatric Infectious Disease Journal, 28, 118–122.

    Article  PubMed  Google Scholar 

  • Salo, H., Sintonen, H., Nuorti, J. P., Linna, M., Nohynek, H., Verho, J., & Kilpi, T. (2005). Economic evaluation of pneumococcal conjugate vaccination in Finland. Scandinavian Journal of Infectious Diseases, 37(11–12), 821–832.

    Article  PubMed  Google Scholar 

  • Skoczynska, A., Sadowy, E., Bojarska, K., Strzelecki, J., Kuch, A., Gołębiewska, A., Wasko, I., Forys, M., van der Linden, M., & Hryniewicz, W. (2011). Participants of laboratory-based surveillance of community acquired invasive bacterial infections (BINet). The current status of invasive pneumococcal disease in Poland. Vaccine, 29(11), 2199–2205.

    Article  PubMed  Google Scholar 

  • Sulikowska, A., Grzesiowski, P., Sadowy, E., Fiett, J., & Hryniewicz, W. (2004). Characteristics of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis isolated from the nasopharynges of asymptomatic children and molecular analysis of S. pneumoniae and H. influenzae strain replacement in the nasopharynx. Journal of Clinical Microbiology, 42, 3942–3949.

    Article  PubMed  CAS  Google Scholar 

  • Williams, B. G., Gouws, E., Boschi-Pinto, C., Bryce, J., & Dye, C. (2002). Estimates of world-wide distribution of child deaths from acute respiratory infections. The Lancet Infectious Diseases, 2, 25–32.

    Article  PubMed  Google Scholar 

  • Wisloff, T., Abrahamsen, T. G., Bergsaker, M. A., Løvoll, Ø., Møller, P., Pedersen, M. K., & Kristiansen, I. S. (2006). Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program. Vaccine, 24(29–30), 5690–5699.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Supported by CMKP grant 501-1-1-19-42/2009.

Conflicts of interest: The authors declare no conflicts of interest in relation to this article.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Teresa Jackowska .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media Dordrecht

About this paper

Cite this paper

Jackowska, T., Zaleska-Ponganis, J., Dziurda, D. (2013). Invasive Pneumococcal Bacteremia in a 9-Year-Old Boy Caused by Serotype 1: Course, Treatment and Costs. In: Pokorski, M. (eds) Respiratory Regulation - Clinical Advances. Advances in Experimental Medicine and Biology, vol 755. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-4546-9_33

Download citation

Publish with us

Policies and ethics